U.S. markets closed

Vertex Pharmaceuticals Incorporated (VRTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
267.15-3.70 (-1.37%)
At close: 4:00PM EDT

267.15 0.00 (0.00%)
After hours: 4:00PM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close270.85
Open270.06
Bid265.01 x 800
Ask267.40 x 1400
Day's Range266.88 - 272.73
52 Week Range165.23 - 306.08
Volume949,935
Avg. Volume1,706,704
Market Cap69.584B
Beta (5Y Monthly)0.88
PE Ratio (TTM)33.72
EPS (TTM)7.92
Earnings DateOct 28, 2020 - Nov 02, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est306.04
  • 2 Revolutionary Biotech Stocks to Buy Right Now
    Motley Fool

    2 Revolutionary Biotech Stocks to Buy Right Now

    Here's a simple argument for why long-term investors should consider buying shares of biotech companies. Since its inception in 2006, the SPDR S&P Biotech Index -- an industry benchmark -- has crushed the S&P 500, as the graph below shows. This graph doesn't show us the specific biotech stocks that performed well throughout this period, and we can't assume the trend will continue indefinitely; after all, the market is forward-looking.

  • Invest $5,000 in These 3 Stocks to Ride Out the Recession Without Worries
    Motley Fool

    Invest $5,000 in These 3 Stocks to Ride Out the Recession Without Worries

    People across the world increased their online buying during the coronavirus-related lockdowns. As the largest e-commerce retailer in the world, Amazon was a prime beneficiary. The convenience of shopping online, combined with continued worries about COVID-19, should keep Amazon's sales momentum going even if the recession continues for a much longer period.

  • Vertex (VRTX) Q2 Earnings & Sales Beat, Revenue Guidance Up
    Zacks

    Vertex (VRTX) Q2 Earnings & Sales Beat, Revenue Guidance Up

    Vertex (VRTX) raises its revenue guidance on the strong uptake of its newest CF drug, Trikafta. Shares rise in after-hours trading.